Kazia Therapeutics (KZIA) Non-Current Deffered Revenue (2016)
Kazia Therapeutics (KZIA) posted Non-Current Deffered Revenue of $613157.0 for Q4 2016, up 16.71% on a QoQ basis from $525379.1 in Q2 2016.
Kazia Therapeutics (KZIA) has 1 years of Non-Current Deffered Revenue data on file, last reported at $613157.0 in Q4 2016.
- In Q4 2016, Non-Current Deffered Revenue changed N/A year-over-year to $613157.0; the TTM figure through Dec 2016 stood at $613157.0 (changed N/A YoY), while the FY2016 annual figure was $512780.6, changed N/A from the prior year.
- Non-Current Deffered Revenue climbed to $613157.0 in Q4 2016, from $525379.1 in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $613157.0 in Q4 2016 and bottomed at $525379.1 in Q2 2016.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 225.10 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Kazia Therapeutics | 1.55 Bn | 1.55 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2016 | 613,156.97 |
| Jun 30, 2016 | 525,379.07 |